J&J Buys $440 Mil. Stake In Crucell; Will Collaborate On Universal Flu Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J follows its brethren into vaccines, and Crucell lands a big-pharma partner in the wake of its failed deal with Wyeth.
You may also be interested in...
J&J's Van Hoof Talks About Expanding Vaccines Development
A pair of technology platforms acquired in the 2010 buyout of Crucell is enabling J&J to produce higher yields of vaccines and deliver safely using adenovirus vectors.
Deals Of The Week: J&J/Crucell, Merck/Beijing Genomics Institute …
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
Deals Of The Week: J&J/Crucell, Merck/Beijing Genomics Institute …
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.